Department of Pediatric Infectious Diseases, Dr. Behçet Uz Children's Diseases and Surgery Training and Research Hospital, İzmir, Turkey.
Division of Pediatric Intensive Care Unit, Dr. Behcet Uz Children's Disease and Pediatric Surgery Training and Research Hospital, Izmir, Turkey.
J Mycol Med. 2022 Aug;32(3):101277. doi: 10.1016/j.mycmed.2022.101277. Epub 2022 Apr 6.
Candida species are among the most prevalent microorganisms in pediatric critical care units that cause central line-associated bloodstream infections. The goal of this study was to assess the therapeutic benefit of central line bundle for the prevention of Candida species-related bloodstream infections in pediatric intensive care units.
The study covered the period from January 1, 2009, to December 31, 2019. Pre-bundle and bundle phases were included in the research. The Clinical Microbiology Laboratory's records revealed episodes of Candida-related central line-associated bloodstream infections.
The study was conducted in the Dr. Behçet Uz Child Disease and Pediatric Surgery Training and Research Hospital's PICU (which has 24 beds and admits 350 patients per year).
This study included pediatric patients in the pediatric intensive care unit with non-tunneled central venous catheters.
In the pediatric intensive care unit, a central line bundle was started.
A total of 236 Candida-related central line-associated bloodstream infections were discovered during the study period. Non-albicans Candida accounted for 83.5% (197) of the total, whereas C.albicans accounted for 16.5%(39). During the pre-bundle period, 137 Candida species were isolated from the patients, while 99 Candida species were isolated during the bundle period. Candida-related central line-associated bloodstream infections dropped from 13.68 to 5.93 per 1000 CL-days after the central line bundle was used (p < 0.001).
According to our findings, the central line bundle greatly reduced central line-associated Candida species bloodstream infections. Central line bundles are an effective scientific solution for preventing Candida-related central line-associated bloodstream infections in hospitals with high Candida prevalence.
念珠菌属是儿科重症监护病房中最常见的微生物之一，可引起中心静脉导管相关血流感染。本研究旨在评估中心静脉导管套件在预防儿科重症监护病房念珠菌属相关血流感染方面的治疗效果。
研究时间为 2009 年 1 月 1 日至 2019 年 12 月 31 日。研究包括套件使用前和套件使用阶段。临床微生物学实验室的记录显示了与念珠菌相关的中心静脉导管相关血流感染的发生情况。
本研究在贝赫切特·乌兹儿童疾病和小儿外科培训与研究医院的儿科重症监护病房（拥有 24 张床位，每年收治 350 名患者）进行。
本研究纳入了儿科重症监护病房中使用无隧道中心静脉导管的儿科患者。
在儿科重症监护病房中，开始使用中心静脉导管套件。
研究期间共发现 236 例与念珠菌相关的中心静脉导管相关血流感染。非白念珠菌念珠菌占总数的 83.5%（197 例），而 C.albicans 占 16.5%（39 例）。在套件使用前阶段，从患者中分离出 137 株念珠菌属，而在套件使用阶段分离出 99 株念珠菌属。使用中心静脉导管套件后，念珠菌相关中心静脉导管相关血流感染率从 13.68 降至 5.93/1000 中心静脉导管日（p<0.001）。
根据我们的发现，中心静脉导管套件大大降低了中心静脉导管相关念珠菌属血流感染的发生率。对于念珠菌属流行率较高的医院，中心静脉导管套件是预防念珠菌属相关中心静脉导管相关血流感染的有效科学解决方案。
